Inactive Instrument

News Iovance Biotherapeutics Inc Nasdaq

Equities

US53619R1023

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting	Apr. 24	AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4) - April 19, 2024	Apr. 22	AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	Apr. 19	AQ
General (Ret.) Merrill A. McPeak, Member of the Board of Directors of Iovance Biotherapeutics, Inc. Retires and Not Stands for Re-Election	Mar. 29	CI
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	Mar. 25	AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	Mar. 22	AQ
Piper Sandler Adjusts Iovance Biotherapeutics Price Target to $19 From $18, Maintains Overweight Rating	Mar. 14	MT
Transcript : Iovance Biotherapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:45 AM	Mar. 12
Iovance Biotherapeutics to Present at Upcoming Conferences	Mar. 04	AQ
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday	Mar. 04	MT
Iovance Biotherapeutics Says FDA Lifts Partial Clinical Hold on Lung Cancer Study	Mar. 04	MT
Iovance Biotherapeutics Syas FDA Lifts Partial Clinical Hold on LN-145	Mar. 04	DJ
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer	Mar. 04	AQ
Iovance Biotherapeutics Announces Fda Has Lifted Clinical Hold on the Iov-Lun-202 Registrational Trial in Non-Small Cell Lung Cancer	Mar. 04	CI
Iovance Biotherapeutics to Present at Upcoming Conferences	Mar. 01	AQ
Wells Fargo Adjusts Price Target on Iovance Biotherapeutics to $25 From $22, Maintains Overweight Rating	Mar. 01	MT
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates	Feb. 29	AQ
Barclays Raises Price Target on Iovance Biotherapeutics to $22 From $18, Maintains Overweight Rating	Feb. 29	MT
Iovance Biotherapeutics Q4 Loss Narrows, Posts Revenue	Feb. 29	MT
Iovance Biotherapeutics: Q4 Earnings Snapshot	Feb. 28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Iovance Biotherapeutics Inc Nasdaq

Equities

US53619R1023

Summary

Filters